Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes.
Araki E, Kawamori R, Inagaki N, Watada H, Hayashi N, Horie Y, Sarashina A, Thiemann S, von Eynatten M, Dugi K, Woerle HJ. Araki E, et al. Among authors: von eynatten m. Diabetes Obes Metab. 2013 Apr;15(4):364-71. doi: 10.1111/dom.12039. Epub 2012 Dec 7. Diabetes Obes Metab. 2013. PMID: 23163910 Clinical Trial.
Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.
Kawamori R, Inagaki N, Araki E, Watada H, Hayashi N, Horie Y, Sarashina A, Gong Y, von Eynatten M, Woerle HJ, Dugi KA. Kawamori R, et al. Among authors: von eynatten m. Diabetes Obes Metab. 2012 Apr;14(4):348-57. doi: 10.1111/j.1463-1326.2011.01545.x. Epub 2012 Jan 17. Diabetes Obes Metab. 2012. PMID: 22145698 Clinical Trial.
Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
Barnett AH, Patel S, Harper R, Toorawa R, Thiemann S, von Eynatten M, Woerle HJ. Barnett AH, et al. Among authors: von eynatten m. Diabetes Obes Metab. 2012 Dec;14(12):1145-54. doi: 10.1111/dom.12011. Epub 2012 Oct 1. Diabetes Obes Metab. 2012. PMID: 22974280 Clinical Trial.
Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years.
Schernthaner G, Barnett AH, Patel S, Hehnke U, von Eynatten M, Woerle HJ. Schernthaner G, et al. Among authors: von eynatten m. Diabetes Obes Metab. 2014 Nov;16(11):1078-86. doi: 10.1111/dom.12321. Epub 2014 Jul 3. Diabetes Obes Metab. 2014. PMID: 24865132 Clinical Trial.
Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double-blind, active-controlled, parallel group, multinational clinical trial.
Ross SA, Caballero AE, Del Prato S, Gallwitz B, Lewis-D'Agostino D, Bailes Z, Thiemann S, Patel S, Woerle HJ, von Eynatten M. Ross SA, et al. Among authors: von eynatten m. Diabetes Obes Metab. 2015 Feb;17(2):136-44. doi: 10.1111/dom.12399. Epub 2014 Nov 19. Diabetes Obes Metab. 2015. PMID: 25298165 Clinical Trial.
Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trial.
Gallwitz B, Rosenstock J, Patel S, von Eynatten M, Hehnke U, Mehlburger L, Dugi KA, Woerle HJ. Gallwitz B, et al. Among authors: von eynatten m. Diabetes Obes Metab. 2015 Mar;17(3):276-84. doi: 10.1111/dom.12419. Epub 2015 Jan 9. Diabetes Obes Metab. 2015. PMID: 25425502 Clinical Trial.
133 results